Black Diamond Therapeutics
BDTX
BDTX
90 hedge funds and large institutions have $218M invested in Black Diamond Therapeutics in 2024 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 25 increasing their positions, 19 reducing their positions, and 27 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
90
Holders Change
+2
Holders Change %
+2.27%
% of All Funds
1.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
31
Increased
25
Reduced
19
Closed
27
Calls
$331K
Puts
$116K
Net Calls
+$215K
Net Calls Change
+$23K
Top Buyers
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$18.3M |
| 2 |
VPC
Vestal Point Capital
New York
|
+$9.79M |
| 3 |
BlackRock
New York
|
+$8.56M |
| 4 |
ABG
Ally Bridge Group
New York
|
+$3.89M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.79M |
Top Sellers
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$17.9M |
| 2 |
LCM
Laurion Capital Management
New York
|
-$4.45M |
| 3 |
BOCH
Blue Owl Capital Holdings
New York
|
-$3.52M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.86M |
| 5 |
Jane Street
New York
|
-$1.27M |
